NasdaqHealth CareHealth Care TechnologyS&P SmallCap 600
$12.05
-0.13 (-1.07%)
Close of Nov 06, 2026 · end-of-day data
CERT 8-K filings in 2025
Every material Form 8-K Certara filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Certara appointed Jon Resnick, president of IQVIA's U.S. and Canada regional business, as chief executive officer effective January 1, 2026, succeeding William Feehery, who departs as CEO and director on December 31, 2025. Resnick also joins the board, and the company reaffirmed its 2025 full-year financial outlook, which means the leadership change does not come with a revised forecast.
Resnick receives an initial annual base salary of $750,000 and a target bonus of 100% of salary.
A make-whole restricted stock unit grant with a target value of $6,500,000 vests over the first two yearly anniversaries of the start date.
Feehery will receive a consulting fee of $20,000 per month and pro-rata vesting of equity awards granted in May 2025; either party can end the consulting arrangement with five days' notice.
The company reaffirmed its 2025 full-year financial outlook, as previously disclosed on November 6, 2025.
Certara reported third-quarter 2025 revenue of $104.6 million, up 10% from a year earlier, and swung to net income of $1.5 million from a net loss of $1.4 million. The company raised its 2025 profitability targets and narrowed full-year revenue guidance to $415 million to $420 million, though services bookings fell 9% and management cited spending hesitancy in parts of the services business.
Q3 2025 revenue was $104.6 million, up 10%; software revenue rose 22% to $43.8 million and services revenue rose 3% to $60.8 million
Q3 net income was $1.5 million, or $0.01 per diluted share, versus a net loss of $1.4 million a year earlier; adjusted EBITDA was $35.2 million, up 7%
Full-year 2025 guidance: revenue of $415 million to $420 million, adjusted EBITDA margin of about 32%, and adjusted diluted EPS of $0.45 to $0.47
Q3 services bookings were $55.8 million, down 9% year over year, mainly from softer tier-one customer trends in regulatory services
Certara, Inc. and its subsidiaries entered into a Sixth Amendment to its credit agreement on October 16, 2025, creating Replacement Term Loans that refinanced existing term loans. The company says the amendment reduces its borrowing cost and should produce interest expense savings. The filing does not state the size of the loans or the amount of savings.
Replacement Term Loans were funded in full on October 16, 2025, and used to refinance existing term loans.
Term SOFR option carries a 0.00% floor plus a 2.75% margin; ABR option carries a 1.00% floor plus a 1.75% margin.
Bank of America, N.A. is administrative agent and collateral agent; guarantees, collateral, prepayment and covenant terms are substantially similar to prior terms.
Certara reported second-quarter 2025 revenue of $104.6 million, up 12% from a year earlier, and its net loss narrowed to $2.0 million from $12.6 million. The company reiterated its full-year 2025 guidance, including revenue of $415 million to $425 million, which means the outlook was neither raised nor cut.
Revenue $104.6 million, up 12%; software revenue $46.7 million, up 22%; services revenue $57.9 million, up 5%
Net loss $2.0 million, versus $12.6 million in Q2 2024; diluted loss per share $(0.01) versus $(0.08)
Adjusted EBITDA $31.9 million, up 21% from $26.3 million
Full-year 2025 guidance reiterated: revenue $415 million to $425 million; adjusted diluted EPS $0.42 to $0.46
Certara reported first-quarter 2025 revenue of $106.0 million, up 10% from a year earlier, and net income of $4.7 million, compared with a net loss of $4.7 million in the prior-year quarter. The company reiterated its full-year 2025 guidance, including revenue of $415 million to $425 million, so shareholders have no new change to the outlook.
Revenue was $106.0 million, up 10% from $96.7 million in Q1 2024; software revenue rose 18% to $46.4 million.
Net income was $4.7 million, or $0.03 per diluted share, versus a net loss of $4.7 million in Q1 2024.
Adjusted EBITDA was $34.8 million, up 20% from $29.1 million.
Full-year 2025 guidance was reiterated: revenue of $415 million to $425 million and adjusted diluted EPS of $0.42 to $0.46.
Certara said preliminary first-quarter 2025 revenue rose 10% to $106.0 million and bookings rose 12% to $118.0 million, and its board approved a $100 million share repurchase authorization. The company reiterated its full-year 2025 guidance and said Arsenal Capital Partners agreed to a one-year lock-up on certain shares, which bars most transfers until April 14, 2026.
Preliminary Q1 2025 revenue of $106.0 million, up 10% from $96.7 million; software revenue up 18% to $46.4 million
Preliminary Q1 2025 adjusted EBITDA of $33 million to $35 million, up 13% to 20% from $29.1 million; the figures are unaudited and may change
Full-year 2025 revenue guidance of $415 million to $425 million was reiterated
Arsenal lock-up runs until April 14, 2026; the $100 million buyback may be suspended or terminated at any time
Certara said Dr. Patrick F. Smith stepped down as President of Certara Drug Development Solutions effective March 3, 2025. He will remain with the company in a senior advisory and scientific role. The filing does not name a successor or describe any change to financial results.
Dr. Patrick F. Smith stepped down as President, Certara Drug Development Solutions, effective March 3, 2025
Smith will remain employed by Certara in a senior advisory and scientific role
The filing was dated March 5, 2025 and does not name a replacement
Certara reported fourth-quarter 2024 revenue of $100.4 million, up 14% from a year earlier, and net income of $6.6 million, compared with a net loss of $12.5 million in the prior-year quarter. The company also issued full-year 2025 guidance, forecasting revenue of $415 million to $425 million and adjusted diluted EPS of $0.42 to $0.46.
Q4 2024 revenue was $100.4 million, up 14%; software revenue rose 26% to $42.3 million
Q4 2024 diluted EPS was $0.04 versus a loss of $0.08; adjusted EBITDA was $33.5 million, up 13%
2025 guidance: revenue of $415 million to $425 million and adjusted EBITDA margin of 30% to 32%
Full-year 2024 net loss narrowed to $12.1 million from $55.4 million in 2023
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Certara filing is on SEC EDGAR ↗. 8-K briefs of other companies →